19 November 2012
Oxford BioTherapeutics Sign Major Strategic Collaboration with Menarini Group
Portfolio company Oxford BioTherapeutics has announced a major innovative and strategic alliance with Menarini to develop a portfolio of antibody based drugs in the field of cancer. The agreement covers five of OBT's antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via a different novel oncology target.
This deal brings together OBT's discovery expertise with Menarini's clinical knowledge and expanding capabilities in the manufacture and development of biologics to build value for both companies as they work to bring this exciting portfolio of next generation antibody-based cancer drugs to market.
Christian Rohlff, CEO of OBT, commented, "I am delighted to collaborate with Menarini, a company that has made impressive achievements in biologics development and demonstrated an enduring commitment to the development of innovative cancer therapies. This creative alliance is transformational for us as it allows OBT to participate in the clinical development and future commercialisation of our programs while at the same time it bolsters Menarini's pipeline with a portfolio of the next generation of cancer drugs. We believe this innovative business framework could become the business model of choice for rapidly growing biotechnology companies seeking new ways to develop their drug pipeline effectively."